Innovative Oncology Immunotherapy Efficacy Evaluation Platform Chuangmo Biotech Completes Tens-of-Millions RMB Series A Financing

VCBeat (WeChat ID: VCBEAT) has learned that in early 2021, Chuangmo Biotechnology (Beijing) Co., Ltd. successfully closed its first round of financing, amounting to tens of millions of RMB. The financing agreement was signed in late 2020. This round was jointly invested by Dalton Venture and Yusen Capital.

Chuangmo Biotechnology (Beijing) Co., Ltd. was formerly known as Beijing Feinuoke Biotechnology Co., Ltd. Established in 2016, the company specializes in CRO services for pharmacodynamics of oncology and tumor immunotherapy. Since its inception, the company has been dedicated to the development of next-generation in vitro and experimental animal models for pharmacodynamic studies in oncology and tumor immunology. By leveraging innovative mouse models, delivering stable high-quality products, and adhering to rigorous experimental protocols, it provides domestic and international new drug developers with pharmacodynamic data that closely mirror clinical efficacy responses. Its clientele includes renowned pharmaceutical companies, innovative biotechnology firms, and research institutions both in China and abroad. In October 2020, the company completed an equity restructuring, was officially renamed Chuangmo Biotechnology (Beijing) Co., Ltd., and successfully established its subsidiary, Chuangmo Pharmaceutical Technology (Beijing) Co., Ltd.

In the development of novel therapeutics for oncology and tumor immunotherapy, limitations in research models have led to significant discrepancies between clinical efficacy outcomes and preclinical results, resulting in persistently high failure rates during clinical trials. A key concern for new drug developers has long been how to obtain preclinical data that closely mirrors actual clinical efficacy responses, thereby mitigating the risks associated with clinical trials. Leveraging its proprietary next-generation NIG severe combined immunodeficient (SCID) mice, Chuangmo Biotechnology has developed multiple humanized tumor immunotherapy efficacy evaluation platforms, as well as a dual-humanized platform combining the immune system with patient-derived xenografts (PDX), to address the diverse needs of new drug developers. The company’s core team comprises professionals from renowned pharmaceutical companies in China and the United States, bringing extensive experience and qualifications in the development of model organisms. With branches in Beijing, Shanghai, and Shenzhen, the company currently employs a dedicated team of over 30 individuals committed to serving new drug developers.

Dr. Liu Jin, Founder and Chairman of Chuangmo Biotech, stated: “Chuangmo Biotech has consistently adhered to a core strategy of innovation, continuously developing and optimizing its humanized tumor immuno-oncology efficacy platform to ensure that preclinical efficacy results more closely mirror clinical responses, thereby serving developers of novel immuno-oncology therapeutics. We extend our gratitude to Dalton Venture and Yusen Capital for their recognition of our company and team, as well as for their professional expertise and capital support. The completion of this financing round has injected fresh momentum into Chuangmo Biotech. We are confident in our ability to provide more powerful drug development tools to global innovators in the future. Leveraging the favorable industry trends, we aim to contribute to new drug research and development in China and worldwide, making our modest contribution to alleviating patient suffering.”

Mr. Sun Qi, Founding Managing Partner of Dalton Venture, stated: “In the future, China will see an increasing emergence of First-in-class drugs, particularly in the field of tumor immunotherapy. Therefore, humanized tumor immunotherapy efficacy platforms that more closely reflect clinical pharmacodynamic responses have become increasingly important. Chuangmo Biology boasts a world-class R&D and entrepreneurial team and is continuously optimizing its tumor immunotherapy efficacy platform. We strongly endorse this approach and are delighted to participate in supporting Chuangmo Biology’s further development, thereby contributing to the advancement of China’s biopharmaceutical CRO industry.”

Mr. Li Kechun, Founder and Executive Director of Yusen Capital, stated: “Chuangmo Bio possesses next-generation immunodeficient mouse models with independent intellectual property rights, a leading humanized tumor immunotherapy efficacy evaluation platform, and a world-class R&D and entrepreneurial team. In light of recent breakthroughs in global biomedical research and innovative drug development, the company is poised to establish a comprehensive, closed-loop business model. Leveraging its tumor immunotherapy evaluation platform, Chuangmo Bio will integrate resources from patients, pharmaceutical companies, research institutions, and hospitals to provide patients with treatment options and access to new drug clinical trials, offer pharmaceutical companies efficacy predictions and clinical patient data, support physicians in translational medical research, and supply experimental model services to research institutions. Yusen Capital looks forward to partnering with Chuangmo Bio to jointly advance the development and progress of novel drug target discovery, innovative drug creation, and precision medication guidance for patients.”

About Dalton Venture: Dalton Venture focuses on early-to-mid-stage investments and industrial M&A in the healthcare sector, with investment areas covering medical devices, healthcare services, biopharmaceuticals, and healthcare informatics. The core team members all come from the healthcare industry, possessing extensive experience in corporate operations management, investment, and mergers and acquisitions. They have both entrepreneurial experience in incubating early-stage companies and experience in managing listed companies with market capitalizations reaching tens of billions. In the field of medical innovation technology, Dalton Venture has made in-depth strategic layouts. The Dalton Venture team is highly stable and has built a robust investment ecosystem. Leveraging profound industry expertise and extensive, high-quality industry resources, it provides strong post-investment support to create high-value returns for its partners.

About Yusen Capital: Beijing Yusen Equity Investment Co., Ltd. was established in 2016 as an entrepreneurial and investment-financing platform integrating innovative technology research, angel investment, venture capital, and investment banking services. The team brings together top scientists, industry experts, and investment specialists in the biomedical field. Focusing on the most promising international sectors—including biopharmaceuticals, medical devices, and life science technologies—Yusen Capital identifies, nurtures, and builds innovative enterprises with significant capital value and commercial potential. It provides comprehensive entrepreneurial resources and services, encompassing ideation, funding, management, business modeling, strategic planning, industrial implementation, and capital operations. Leveraging its expertise, resources, and experience in technology, entrepreneurship, and capital, Yusen Capital helps companies and startup teams avoid pitfalls, achieve steady and rapid growth, and attain business success, ultimately delivering substantial returns to investors. In recent years, Yusen Capital has served and invested in more than 30 companies.